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A R T I C L E  I N F O A B S T R A C T
Some laboratory tests or biomarkers are used as sur-
rogate outcomes for health care effectiveness. HbA1c 
is defined as a surrogate biomarker since HbA1c val-
ues have been approved to be used in predictions of 
clinically important complications of diabetes melli-
tus. With the advance of information technology (IT) 
the real life data are aggregating as electronic health 
records (EHRs). About 70-85% of individuals admit-
ted to hospitals have laboratory test results. As such, 
medical laboratories are the data centers in the hos-
pitals. The test results can be used for assessment of 
health care delivered, especially for chronic diseases. 
This information provides insights of healthcare ser-
vices, and can be used to enhance for individual and 
population well-being, research, and education. This 
article focuses on the importance of using laboratory 
tests results as outcome measures for specific popu-
lation health status that are important in assessing 
the quality of health care services. The findings from 
our studies on the diabetic care quality is presented. 
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INTRODUCTION
Medical laboratories are one of the key players 
in the provision of healthcare, and responsible 
for healthcare quality. In order to create value-
based health care, population-level outcomes 
and cost-effectiveness should be measured as 
well at the patient-level (1). The test results from 
the electronic health records can be used for get-
ting information about population-level health-
care quality, especially for chronic diseases. In 
this context, laboratory professionals can pres-
ent some valuable information about the quality 
of care to the health policy makers, since 70-85% 
of individuals admitted to a hospital have labora-
tory tests (2).
It is suggested that quality of care can be as-
sessed according to the conceptualized frame-
works suggested by Donabedian and the World 
Health Organization, and randomized controlled 
trials (RCTs) are suggested as the best model for 
assessment. However, RCTs of diagnostic proce-
dures are not common because of the challenges 
in design and implementation (3-9). Electronic 
health records are providing new oppurtuni-
ties with high data collection capacity and can 
be used for assessment of the population status 
with specific disease according to the surrogate 
outcome measures such as HbA1c for diabetes 
monitoring. Although the information obtained 
from the real life data is not enough for determi-
nation of the actual status, it can provide insights 
into further structured outcome studies. The 
data can be used by policy makers, especially in 
countries where no outcome assessments have 
been performed at the patient and/or popula-
tion level. Laboratory professionals working in 
hospitals should have sufficient knowledge and 
skills in data management for extracting mean-
ingful information from patients’ test results 
besides their core professional knowledge. The 
objectives of this paper are to emphasize roles 
of medical laboratory professionals in the value-
based health care model, present the examples 
on diabetes care quality, and to point out what 
competencies should be gained by laboratory 
professionals.
HEALTH CARE QUALITY MEASURES,  
OUTCOMES AND VALUE-BASED  
HEALTH CARE
Quality measures have been used in order to as-
sess and compare the healthcare quality of an 
organization, quality of health care delivery ser-
vices, and population health quality (3). The per-
formance of health care is assessed by outcome 
measures. The “value-based health care-VBHC” 
Data from our 6-month cohort study of 3 hospitals in different regions in Turkey (11).
Targets: HbA1c <53 mmol/mol (7%) (American Diabetes Association. Standards of medical care in diabetes, 2004). 
Hospital
Poor controlled diabetics (%)
0. month 6. month
Hospital A 19 14
Hospital B 53 39
Hospital C 52 22
Table 1 Percentages of  patients who have test values outside the HbA1c targets 
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model that is implemented in the US aims to in-
crease the value that is provided from healthcare 
services available for a population (1). A report 
prepared according to the laboratory test results 
for specific disease population extracted from 
EHRs can provide an overall look about all the 
key supporting elements of the VBHC model. 
ELECTRONIC HEALTH RECORDS, BIG DATA, 
POPULATION HEALTHCARE QUALITY
The EHRs are being recognized as an important 
tool for research as well as clinical care. The main 
objective should be to learn data mining tech-
niques for extracting meaningful information 
from database obtained from the EHRs. Some 
countries have been establishing systems for en-
hancing the data mining capacities of relevant 
organizations (4,5). The laboratory profession-
als with their data mining knowledge comple-
mented with their core professional knowledge 
should be part of the data management teams 
at the hospitals along with epidemiologists and 
data scientists. They provide meaningful infor-
mation from test results as a basis for tracking 
chronic diseases and insights into public health 
trends, and can aid the management of public 
healthcare policies (6,7). 
DIABETES CARE QUALITY, 
HbA1c AND BIG DATA 
Quality indicators for several diseases, for ex-
ample, diabetes care quality, are being defined 
by government organizations and by scientific 
societies (8,9). Most of quality measurement in 
Figure 1 Six month-cohort study on diabetic populations of  three hospitals 
from three different regions of  Turkey (2003-2004)

























Hospital A is in the Western Part of Turkey (n=48), Hospital B in the South Eastern Part (n=145), and Hospital C is in the 
Shouthern (n=23). A an B are university hospitals, C is aprivate hospital. 
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Figure 2 Monthly HbA1c distributions of  diabetics in 2017 




N= 4 691 (M: 1 921, F: 2 770) 
Good controlled DM: 44.6% 
N= 4 286 (M: 1 254, F: 3 032) 
Good controlled DM: 63.7% 
A is a university hospital, B is a private hospital.
Target for HbA1c: 53 mmol/L (7.0%).




Surrogate biomarkers for monitoring healthcare quality for chronic diseases such as diabetes care
diabetes mainly includes measures of process 
and intermediate outcomes, such as HbA1c as 
surrogate biomarker (10). Laboratory test re-
sults can be treated as part of indicative data 
and the findings from data mining can provide 
meaningful knowledge to the policy makers at 
national and individual levels.
DIABETIC CARE QUALITY TRACKING 
FOCUSING ON THE HbA1c LEVELS  
OF PATIENTS WITH DIABETES MELLITUS 
The HbA1c values of diabetics admitted to the 
hospitals were collected for 40 years together 
with the evidence for the analytical quality as-
surance. In the first 12 years, there were no 
electronic health records. The test results of 
diabetics were recorded on their “diabetes test 
follow-up cards”. Our laboratory collected the 
results of glucose, HbA1c, and lipids tests and 
estimated the percentages of poorly controlled 
diabetics (1982-1994) and 93% of diabetics had 
HbA1c values higher 7.0% (53 mmol/mol).
Furthermore, HbA1c results of diabetics ad-
mitted to the Center of the Turkish Diabetes 
Society in Denizli between 1999-2003 were also 
collected and 53% of the patients had HbA1c 
values higher than 7.0% (53 mmol/mol). 
The HbA1c distributions established from our 
research studies (2003-2005) and the distribu-
tions obtained from data extracted from the 
LISs (2017) are seen in the Figures 1 and 2, re-
spectively (11,12). The percentages of patients 
that have values outside the targets at the be-
ginning and the 6th month can be seen in the 
Table 1 extracted from our cohort study (11). All 
patient results were collected together with the 
evidence of analytical quality assurance results 
of the laboratories. 
CONCLUSION
Observations and findings from our studies have 
shown that laboratory professionals should be 
part of the data management team in health 
care organizations along with epidemiologists, 
statisticians, data scientists, and professionals 
from relevant disciplines. Laboratory profes-
sionals are one of the key players in health care 
services. They should be aware of the laborato-
ry’s value in improving the health of the popula-
tion, not only the health of a single patient. The 
key issue is to realize what future challenges 
will be and what skills should be gained in order 
to cope with these challenges. Additional skills 
may be acquired to use relevant information 
technology and data mining methods in order 
to be part of the multidisciplinary teams.
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